Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Replimune ...
Reflector
A class action lawsuit was filed against Replimune Group for alleged failure to disclose critical information about its clinical trial data and FDA approval process.Summary
Gainey McKenna & Egleston announced a securities class action lawsuit against Replimune Group (NASDAQ: REPL) filed in the U.S. District Court for Massachusetts. The complaint alleges Defendants failed to disclose that their BLA study design had unresolved FDA concerns, submitted incomplete data from an early analysis (only 40 patients), and made misleading positive statements about the company's prospects. Investors who purchased shares between October 20, 2025, and April 10, 2026, are encouraged to contact the firm before the October 5, 2026, lead plaintiff motion deadline for potential class membership.
(Source：Reflector)